City
Epaper

Australia adds Covaxin to list of 'recognised' COVID-19 vaccines

By ANI | Updated: November 1, 2021 13:05 IST

Australian government on Monday gave recognition to Bharat Biotech's Covaxin COVID-19 vaccine for the purpose of establishing a traveller's vaccination status in the country.

Open in App

Australian government on Monday gave recognition to Bharat Biotech's Covaxin COVID-19 vaccine for the purpose of establishing a traveller's vaccination status in the country.

"Today, the Therapeutic Goods Administration determined that Covaxin (manufactured by BharatBiotech) vaccine would be 'recognised' for the purpose of establishing a traveller's vaccination status," Australia's High Commissioner to India Barry O'Farrell informed in a tweet.

"Importantly, recognition of Covaxin, along with the previously announced recognition of Covishield (manufactured by AstraZeneca India, means many citizens, as well as other countries, will now be considered fully vaccinated on entry to Australia," the High Commissioner added in the tweet.

COVID-19 vaccines are approved for use in Australia by the Therapeutic Goods Administration (TGA) after an assessment and approval process.

"In recent weeks, the TGA has obtained additional information demonstrating these vaccines provide protection and potentially reduce the likelihood that an incoming traveller would transmit COVID-19 infection to others while in Australia or become acutely unwell due to COVID-19," a statement from Australia's Department of Health informed.

Recognition of Covaxin, along with the previously announced recognition of Covishield (manufactured by AstraZeneca, India), means many citizens of India, as well as other countries where these vaccines have been widely deployed, will now be considered fully vaccinated on entry to Australia, the statement said.

"This will have significant impacts for the return of international students, and travel of skilled and unskilled workers to Australia," the statement added.

From 1 November 2021, vaccinated Australians and permanent residents aged 12 and over may depart Australia without the need to seek a travel exemption, the Australian Health Department said.

The UN health body -- World Health Organisation -- has sought additional clarifications from Bharat Biotech, which manufactures Covaxin and a decision on emergency use authorisation is expected early next month.

WHO giving approval for Emergency Use Authorisation for India's indigenous COVID-19 vaccine 'Covaxin' would facilitate the process of assisting other countries, Foreign Secretary Harsh Vardhan Shringla said on Saturday addressing a media briefing on the first day of G20 summit in Rome.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Bharat Biotech InternationalAstrazeneca indiaaustraliaRomeSeven hillsHarsh vardhan shringlaHarsh shringlaBarry o'farrellBarry o farrellBarry o'farrell ao
Open in App

Related Stories

CricketMitchell Starc Retires: Australian Fast Bowler Announces T20I Exit, Says 'Best Way Forward'

EntertainmentNeha Dhupia & Angad Bedi Jet Off to Rome for Birthday Celebrations , Calls It Their First Honeymoon After 8 Years of Marriage!

InternationalAustralia Shooting: Two Police Officers Killed, One Injured in Porepunkah; Town on Lockdown

MumbaiMumbai: Police Register Case Against Man for Cyberstalking and Blackmailing 23-Year-Old Student in Australia

MumbaiMumbai Shocker: Fake Account in Mother’s Name Used to Blackmail Young Woman in Australia, Case Registered

International Realted Stories

InternationalQatar PM says Trump's Gaza ceasefire plan meets key goals, urges all sides to seize momentum

InternationalNationwide strike in Greece over labour laws halts public services

InternationalIsrael thwarts Palestinian attempt to pave over biblical city of Gibeon

InternationalIsraeli forces take control over Gaza's Netzarim axis

InternationalAfghanistan-Pakistan trade slips to USD 1.1 billion in first half of 2025